Another oral H4R antagonist, ZPL-3893787, significantly decreased EASI, SCORED, and IGA 0/1 scores in a randomized, double-blind phase 2 trial in adults with moderate to severe AD. This evidence concerns the gene HRH4 and Alzheimer disease.